| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -20.9 | -24.8 |
| EPS (diluted, $ a share) | $-0.55 | $-29.50 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: LTGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Latigo Biotherapeutics, Inc.: key numbers
- Share price
- $13.76Close, Nov 17
- Market cap
- $912M
- Shares outstanding
- 66.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Latigo Biotherapeutics, Inc.
All →Latigo Biotherapeutics Financial Results
Latigo Biotherapeutics reported Q3 2026 financial results, ending the period with $401 million in cash to fund operations into 2029. The company also announced the appointment of Todd Smith as President and CEO, replacing Nima Farzan, and updated its Phase 3 onzotrigine trial design to include a Percocet comparator arm.
- Term
- Q3 2026
“With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program.”
Todd N. Smith, president and chief executive officer